Another Site Added to the Early Access Program for Radium-223 Chloride (Alpharadin)

The Early Access Committee Announces an Additional Site for Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

We have been able to get Bayer to open another early access site for Alpharedin. This additional site is in Boston, Ma. In addition to this new site there are still three other sites.

This trial will have no placebo and there will not be any cost for the Alpharadin. In certain cirmustances there might be some costs. So check with the site prior to beginning the therapy.

Basic Eligibility Criteria:
• CRPC/HRPC – on hormone therapy with progressive disease
• At least 2 bone metastases – blastic (sclerotic), not lytic
• Some amount of pain/bone pain (must be taking daily meds – even if it’s Tylenol)
• No mets to lung, liver, or brain
• HGB 10.0 or higher
• Previously treated with Taxotere (or have refused Taxotere – patient’s choice)
• 4 weeks since chemo, and No chemo currently planned
• No abiraterone (Zytiga) while on Alpharadin – previous OK
• No previous extensive radiation to bone (> 25% of bone marrow), and No previous Quadramet or Strontium 89